Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 31Carcinoma, Hepatocellular 30Neoplasms 19Carcinoma, Renal Cell 16Melanoma 10Carcinoma, Non-Small-Cell Lung 10Thyroid Neoplasms 9Endometrial Neoplasms 9Squamous Cell Carcinoma of Head and Neck 6Colorectal Neoplasms 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Neoplasm Metastasis 4Liver Neoplasms 4Carcinoma, Transitional Cell 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Recurrence 3Lymphoma 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Carcinoma 3Biliary Tract Neoplasms 3Stomach Neoplasms 2Solid Tumors 2Osteosarcoma 2Lung Neoplasms 2Kidney Neoplasms 2Glioma 2Diabetes Mellitus, Insulin-Dependent, 12 2

Interventions

Paclitaxel 18pembrolizumab 16Cisplatin 16Fluorouracil 15Irinotecan 13tislelizumab 9Oxaliplatin 8Nivolumab 8Docetaxel 8Leucovorin 6Capecitabine 5spartalizumab 4Levoleucovorin 4Carboplatin 4lenvatinib 3durvalumab 3Radiotherapy 3Drug Therapy 3toripalimab 2sintilimab 2regorafenib 2elgemtumab 2atezolizumab 2Itraconazole 2Injections 2Gemcitabine 2Bevacizumab 2130-nm albumin-bound paclitaxel 2tremelimumab 1sitravatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Esophageal Squamous Cell Carcinoma × lenvatinib × Clear all
NCT05319730 2026-05-26

MK-3475-06B

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
230 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT05342636 2025-12-17

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Merck Sharp & Dohme LLC

Phase 1/2 Completed
90 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04949256 2025-12-15

MK-7902-014

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
864 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡